WallStSmart

Codexis Inc (CDXS)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 762% more annual revenue ($606.42M vs $70.39M). INSM leads profitability with a -2.1% profit margin vs -62.5%. CDXS earns a higher WallStSmart Score of 47/100 (D+).

CDXS

Hold

47

out of 100

Grade: D+

Growth: 5.3Profit: 4.0Value: 5.0Quality: 5.0

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CDXS3 strengths · Avg: 9.3/10
Operating MarginProfitability
35.9%10/10

Strong operational efficiency at 35.9%

Revenue GrowthGrowth
81.3%10/10

Revenue surging 81.3% year-over-year

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

CDXS4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$145.39M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-74.9%2/10

ROE of -74.9% — below average capital efficiency

Profit MarginProfitability
-62.5%1/10

Currently unprofitable

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CDXS

The strongest argument for CDXS centers on Operating Margin, Revenue Growth, Price/Book. Revenue growth of 81.3% demonstrates continued momentum.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : CDXS

The primary concerns for CDXS are EPS Growth, Market Cap, Return on Equity.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

CDXS profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.

CDXS carries more volatility with a beta of 2.50 — expect wider price swings.

CDXS is growing revenue faster at 81.3% — sustainability is the question.

CDXS generates stronger free cash flow (20M), providing more financial flexibility.

Bottom Line

CDXS scores higher overall (47/100 vs 39/100) and 81.3% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Codexis Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Codexis, Inc. discovers, develops and sells biocatalysts. The company is headquartered in Redwood City, California.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?